Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy

By LabMedica International staff writers
Posted on 30 Aug 2026

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that destroys motor neurons and can ultimately lead to respiratory failure. More...

Although available treatments offer limited benefit, practical blood-based measures of disease activity remain scarce. Metabolic abnormalities, including altered lipid metabolism and weight loss, are common in ALS, but their relationship to clinical progression has remained unclear. New findings now identify a circulating metabolite signature linked to ALS severity and highlight a compound that slowed motor decline in mouse models while protecting patient-derived motor neurons.

Researchers at Nagoya University identified N-acyl taurines (NATs) in human blood as markers associated with rapid ALS progression and evaluated PF-04457845, a compound that inhibits fatty acid amide hydrolase, the enzyme that degrades NATs. The investigators noted that PF-04457845 has already completed safety testing in humans. The study was published in JCI Insight.

To capture systemic metabolic changes, the team profiled 867 metabolites in blood samples from individuals with fast- and slow-progressing ALS, as well as from healthy volunteers. NATs, which are part of the extended endocannabinoid system, were elevated in rapidly progressive ALS, and the highest levels were associated with shorter survival. The researchers suggested that this increase may reflect an endogenous protective response, raising the possibility that pharmacologically boosting NATs could help protect neurons.

To explore whether this metabolic signal could point to therapeutic strategies, the investigators screened 29 compounds in motor neurons derived from induced pluripotent stem (iPS) cells from ALS patients. PF-04457845 reduced degenerative changes, limited cellular damage, and preserved neurites in vitro. The compound was then administered to eight-week-old ALS model mice to assess its effects in vivo.

Treatment extended median survival to 138 days, compared with 129.5 days in untreated mice, while improving strength and movement and better preserving spinal cord motor neurons. Healthy mice showed no measurable effect. Gene-expression analyses indicated that the drug shifted microglia toward a supportive, anti-inflammatory state and directly altered genes involved in neuronal growth and function. 

With collaborators from Aichi Medical University and Juntendo University, the researchers now plan larger patient studies to evaluate NATs as biomarkers of disease severity and treatment response, while continuing to assess PF-04457845 and other agents that target NATs and the endocannabinoid system.

“Through our reverse translational approach, beginning with patient blood analysis, we identified metabolic changes throughout the body. Based on these findings, we explored new treatments and demonstrated that the potential drug is effective in both patient-derived iPS cells and animal models,” said Professor Masahisa Katsuno, Nagoya University Graduate School of Medicine.

Related Links
Nagoya University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.